Showing 2331-2340 of 7668 results for "".
- AAD Survey: Too Few Folks Use Sun Protection During Outdoor Activitieshttps://practicaldermatology.com/news/aad-survey-too-few-folks-use-sun-protection-during-outdoor-activities/2461735/Although 90% of Americans report protecting themselves from the sun when going to beaches or pools, far fewer plan for it before other outdoor activities, according to a recent American Academy of Dermatology (AAD) survey of more than 1,000 U.S. adults. "The head, neck, arms, and lower legs are ar…
- Call for Papers: JMIR Dermatology Special Theme Issue on Teledermatologyhttps://practicaldermatology.com/news/call-for-papers-jmir-dermatology-special-theme-issue-on-teledermatology/2461734/JMIR Dermatology—the official journal of the International Society of Teledermatology (ISTD)—and the journal’s guest editors welcome submissions to a special theme issue to coincide with the 10th ISTD World Congress held at the 23rd World Congress of Dermatology on July 4 to 7, 2023, in Singapore.…
- FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with DEBhttps://practicaldermatology.com/news/fda-approves-first-topical-gene-therapy-for-treatment-of-wounds-in-patients-with-deb/2461732/The U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gen…
- ASA, Nicklaus Companies, and ahead Partner to Educate Golfers on Sun Safetyhttps://practicaldermatology.com/news/asa-nicklaus-companies-and-ahead-partner-to-educate-golfers-on-sun-safety/2461730/Nicklaus Companies and ahead, a provider of premium golf and leisure headwear, are joining forces with American Skin Association (ASA) to raise awareness about melanoma and educate golfers on the importance of sun safety. Both companies will use their social platforms to provide awareness and educ…
- EltaMD Teams Up With Bravo's Andy Cohen for Skin Cancer Awarenesshttps://practicaldermatology.com/news/eltamd-teams-up-with-bravos-andy-cohen-for-skin-cancer-awareness/2461729/EltaMD has partnered with Andy Cohen and the Melanoma Research Foundation on a social campaign aimed to ignite dialogue surrounding skin cancer, while educating consumers on the importance of skin checks for National Skin Cancer Awareness Month. As part of this initiative, and to encourage daily s…
- Ankit Agarwal Named New VP of Operations at Vialhttps://practicaldermatology.com/news/ankit-agarwal-named-new-vp-of-operations-at-vial/2461727/Ankit Agarwal is Vial’s new VP of Operations. Vial is a next-generation, technology-first contract research organization (CRO) that operates in multiple therapeutic areas including dermatology. Mr. Agarwal joins the team with more than 10 years of experience in strategy and operations. He has …
- AOBiome’s B244 Eases Eczema Symptoms, Helps Tame Itchhttps://practicaldermatology.com/news/aobiomes-b244-eases-eczema-symptoms-helps-tame-itch/2461723/AOBiome Therapeutics, Inc.’s B244 treatment demonstrated significant improvements in eczema severity and itch reduction The Phase 2b clinical data is published in Lancet's eClinicalMedicine. In the trial, 547 patients were assigned to a high-dose, low-dose, or placebo group. The trial was run ac…
- FDA Greenlights Phio Pharmaceuticals' Trial of PH-762 in Skin Cancerhttps://practicaldermatology.com/news/fda-greenlights-phio-pharmaceuticals-trial-of-ph-762-in-skin-cancer/2461721/The U.S. Food and Drug Administration (FDA) has cleared Phio Pharmaceuticals’ Investigational New Drug (IND) application to move ahead with a clinical trial of PH-762 for treating skin cancer. PH-762 is an INTASYL compound that reduces the expression of PD-1, a protein that inhibits T cells’ abili…
- First Subject Dosed in Phase 1 Clinical Study of NM26 for ADhttps://practicaldermatology.com/news/first-subject-dosed-in-phase-1-clinical-study-of-nm26-for-ad/2461718/The first subject has been dosed in the Phase 1 clinical study of Numab Therapeutics’ NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD). This marks the beginning of a combined single ascending dose (SAD) and multiple ascending dose (MAD…
- Skinvive by Juvéderm Scores FDA Nod to Improve Skin Smoothness in Cheekshttps://practicaldermatology.com/news/skinvive-by-juvederm-scores-fda-nod-to-improve-skin-smoothness-in-cheeks/2461717/The U.S. Food and Drug Administration gave its nod to Skinvive by Juvéderm to improve skin smoothness of the cheeks in adults over the age of 21. Skinvive by Juvéderm is the first and only hyaluronic acid (HA) intradermal microdroplet injection for skin smoothness available in the U.S. with result…